How have MRKR shares performed in 2024?

Marker Therapeutics' stock was trading at $5.50 at the beginning of 2024. Since then, MRKR stock has decreased by 25.5% and is now trading at $4.1002. View the best growth stocks for 2024 here .

Are investors shorting Marker Therapeutics?

Marker Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 107,900 shares, a decrease of 27.9% from the March 15th total of 149,700 shares. Based on an average daily volume of 21,000 shares, the short-interest ratio is currently 5.1 days. Currently, 1.7% of the company's stock are sold short. View Marker Therapeutics' Short Interest .

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our MRKR earnings forecast .

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN) , Viking Therapeutics (VKTX) , PhaseBio Pharmaceuticals (PHAS) , SCYNEXIS (SCYX) , Matinas BioPharma (MTNB) , Genocea Biosciences (GNCA) , Strongbridge Biopharma (SBBP) , Flexion Therapeutics (FLXN) , Geron (GERN) and Ionis Pharmaceuticals (IONS) .

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MRKR

Marker Therapeutics (MRKR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MRKR Stock Alerts

$4.10

-0.21 (-4.87%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.09
▼
$4.40
50-Day Range: $3.63
▼
$4.91
52-Week Range: $0.76
▼
$9.68

Volume: 13,050 shs
Average Volume: 21,437 shs
Market Capitalization: $36.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Marker Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Marker Therapeutics Stock (NASDAQ:MRKR)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

MRKR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRKR Stock News Headlines

April 10, 2024 | investing.com

Marker Therapeutics Inc (MRKR)

April 9, 2024 | msn.com

Putnam Marker Honoring Warner Sisters Restored At Foundry Point Park

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | globenewswire.com

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

April 3, 2024 | finance.yahoo.com

Global Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular Diseases

March 26, 2024 | msn.com

Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M

March 25, 2024 | globenewswire.com

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

March 22, 2024 | globenewswire.com

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 22, 2024 | msn.com

Judge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party Leader

March 14, 2024 | finance.yahoo.com

Global Marker Pens Market Projected to Reach $492.3 Million by 2030, Driven by a Robust CAGR of 5.2%

March 13, 2024 | msn.com

Eliminate Marker Stains From Brick Surfaces With A Handy Hydrogen Peroxide Trick

March 12, 2024 | finance.yahoo.com

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

February 16, 2024 | usatoday.com

Legislators: Why are women overlooked for Florida's Historical Marker Program?

February 3, 2024 | msn.com

EXPO Low Odor Dry Erase Marker Starter Set, Now 29% Off

January 22, 2024 | finance.yahoo.com

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

December 21, 2023 | finance.yahoo.com

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

December 12, 2023 | msn.com

PSTX, MRKR and GPRO among pre-market losers

December 11, 2023 | marketwatch.com

Marker Therapeutics Shares Rise on Positive MT-601 Update

December 11, 2023 | finance.yahoo.com

Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

December 4, 2023 | msn.com

PICS: Festive style shines at Anantara The Marker Hotel's Christmas tree event

November 20, 2023 | msn.com

Community dedicates Blue/Gold Star Hwy Marker

November 15, 2023 | businesswire.com

Sales Marker Introduces AI Sales to the World

November 10, 2023 | msn.com

Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M

November 9, 2023 | morningstar.com

Marker Therapeutics Inc MRKR

November 9, 2023 | finance.yahoo.com

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 8, 2023 | msn.com

Blue Star Memorial Highway Marker dedication set for Nov. 9 in Wrightsville Beach

See More Headlines

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MRKR
CUSIP: N/A
CIK: 1094038
Web: www.markertherapeutics.com
Phone: (713) 400-6400
Fax: N/A
Employees: 67
Year Founded: 2018

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,240,000.00
Net Margins: -142.62%
Pretax Margin: -424.10%
Return on Equity: -39.89%
Return on Assets: -25.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.57
Quick Ratio: 5.57

Sales & Book Value

Annual Sales: $3.31 million
Price / Sales: 11.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.58 per share
Price / Book: 2.60

Miscellaneous

Outstanding Shares: 8,900,000
Free Float: 6,757,000
Market Cap: $36.49 million
Optionable: Not Optionable
Beta: 1.50

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Ms. Elizabeth Donnelly
Director of Administration
Mr. Edmund Cheung
Vice President of Human Resources
Dr. Nadia Agopyan Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Monic Stuart M.D.
Chief Medical Officer
Mr. Gerald Garrett
Senior Vice President of Clinical Operations
Dr. Robert Z. Florkiewicz Sr.
Senior Director of Molecular Biology & Virology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed in 2024?: Marker Therapeutics' stock was trading at $5.50 at the beginning of 2024. Since then, MRKR stock has decreased by 25.5% and is now trading at $4.1002.
View the best growth stocks for 2024 here.
Are investors shorting Marker Therapeutics?: Marker Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 107,900 shares, a decrease of 27.9% from the March 15th total of 149,700 shares. Based on an average daily volume of 21,000 shares, the short-interest ratio is currently 5.1 days. Currently, 1.7% of the company's stock are sold short.
View Marker Therapeutics' Short Interest.
When is Marker Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our MRKR earnings forecast.
How were Marker Therapeutics' earnings last quarter?: Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%.

What other stocks do shareholders of Marker Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).
How do I buy shares of Marker Therapeutics?: Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRKR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Marker Therapeutics (MRKR) Stock Price, News & Analysis

About Marker Therapeutics Stock (NASDAQ:MRKR)

MRKR Stock Price History

MRKR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

MRKR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info